Amylocaine
Basic information
- CAS
644-26-8- Standard SMILES
CCC(C)(CN(C)C)OC(=O)c1ccccc1- InChIKey
FDMBBCOBEAVDAO-UHFFFAOYSA-N- Molecular formula
- C14H21NO2
- Average molar mass
- 235.32 g/mol
- Monoisotopic mass
- 235.15722891
Overview
Stovaine is a benzoate ester.
Names & identifiers
- Preferred name
- Amylocaine
- IUPAC
- [1-(dimethylamino)-2-methylbutan-2-yl] benzoate
- English name
- 1-[(dimethylamino)methyl]-1-methylpropyl benzoate
- Molecular formula
- C14H21NO2
- Molecular weight
- 235.32
Names & synonyms
AmylocaineStovaine644-26-8QRW683O56T1-(DIMETHYLAMINO)-2-METHYL-2-BUTANOL BENZOATEDTXSID6047862(1-((dimethylamino)methyl)-1-methyl-propyl) benzoate[1-[(dimethylamino)methyl]-1-methyl-propyl] benzoateRefChem:557965DTXCID2027838211-411-1Amyleine
Show more names
Stovain2-Butanol, 1-(dimethylamino)-2-methyl-, 2-benzoateBenzoic acid 1-[(dimethylamino)methyl]-1-methylpropyl ester
Amylocaine [BAN]1-(Dimethylamino)-2-methylbutan-2-yl benzoate[1-(dimethylamino)-2-methylbutan-2-yl] benzoateEINECS 211-411-1Amylocaine (BAN)1-[(Dimethylamino)methyl]-1-methylpropyl benzoate1-((Dimethylamino)methyl)-1-methylpropyl benzoate2-Butanol, 1-(dimethylamino)-2-methyl-, benzoate
Database identifiers
- CAS
644-26-8- PubChem CID
- 10767
- DTXSID
DTXSID6047862- ChEMBL
CHEMBL1740065- ChEBI
CHEBI:34981- UNII
- QRW683O56T
- EC Number
- 211-411-1
- Nikkaji
- J13.802I
Properties
Computed structural properties
- XLogP
- 3
- Topological polar surface area
- 29.5 Ų
- Hydrogen bond donors
- 0
- Hydrogen bond acceptors
- 3
- Rotatable bonds
- 6
- Heavy atoms
- 17
- Formal charge
- 0
- Complexity
- 247
Experimental & physicochemical properties
Human DrugsPharmaceuticals
Physicochemical properties
- Boiling point
- 377.72 °C · 377.72°C (rough estimate)
- Density
- 1.0247 · 1.0247 (rough estimate)
- refractive index
- 1.5385 · 1.5385 (estimate)
- FDA UNII
- 683 O56T · QRW683O56T
- Toxicity
- 25 mg/kg · LDLo ivn-rat: 25 mg/kg PHREA7 12,262,32
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
- Toxicity
- LDLo ivn-rat: 25 mg/kg PHREA7 12,262,32
Chemistry & industry
Pharmacology
Protein BindingA lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.
Pharmacodynamics
Like all other local anesthetics, amylocaine acts as a membrane stabilizing drug that reversibly decreases the rate of depolarization and depolarization of excitable membranes. In this way, the conduction of neuronal signals for certain bodily movements can be blocked. In particular, when administered for spinal anesthesia, the resultant anesthesia can typically extend from the chest to the legs.
Mechanism of Action
In particular, amylocaine, much like other local anesthetics, bind and blockade voltage gated sodium channels located in the excitable membranes of various sensory receptors. Once blocked, the influx of sodium across the channels and membrane is inhibited. Because the influx of sodium is necessary to facilitate neuronal action potentials and signal conduction across sensory receptor membranes, the influx inhibition subsequently prevents the body reactions that would normally result from the neuronal signals.
Biological Half-LifeA lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.
Metabolism/MetabolitesA lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.
Absorption, Distribution and Excretion
A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.
A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.
A lack of detailed information regarding the specificities of amylocaine relate to a lack of information on its pharmacokinetics at the time of its primary use in the early 1900s.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…